Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 7, 2000, Pages 1617-1622

  Schelonka, Lee P ^a   Siegel, David ^a   Wilson, Matthew W ^b   Meininger, Alex ^a   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; CILIARY BODY EPITHELIUM; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; EPITHELIUM DYSPLASIA; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEOPLASM; OPTIC NERVE; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA;

ANTIBODIES, MONOCLONAL; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CONJUNCTIVA; CONJUNCTIVAL NEOPLASMS; CORNEA; CORNEAL DISEASES; EPITHELIAL CELLS; EYE; EYE NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); TISSUE DONORS;

EID: 0034083154     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Palmer SS. Mitomycin C as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991;98:317-321.
2. Singh. G, Wilson MR, Foster CS. Mitomycin eye drops as treatment for pterygium. Ophthalmology. 1988;95:813-821.
3. Frucht-Pery J, Pe'er J. Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Arch Ophthalmol. 1996;114:1261-1264.
4. Finger PT, Milner MS, McCormick SA. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol. 1993;77:751-753.
5. Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology. 1999;106:72-79.
6. Wilson MW, Hungerford JL, George SM, Madreperla SA. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol. 1997;124:303-311.
7. Frucht-Pery J, Sugar J, Baum J, et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia. Ophthalmology. 1997;104:2085-2093.
8. Grossniklaus HE, Aaherg TM. Mitomycin treatment of conjunctival intraepithelial neoplasia (editorial). Am J Ophthalmol. 1997;124: 381-383.
9. Heigle TJ, Stulting RD, Palay DA. Treatment of recurrent conjunctival epithelial neoplasia with mitomycin C. Am J Ophthalmol. 1997;124:397-399.
10. Spoor TC, McHenry JG, Shin DH. Long-term results using adjunctive mitomycin C in optic nerve sheath decompression or pseudotumor cerebri. Ophthalmology. 1995;102:2024-2028.
11. Kersten RC, Kulwin DR Mitomycin C in optic nerve sheath decompression (letter). Ophthalmology. 1996;103:864-865.
12. Yu HG, Chung H. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits Kor J Ophthalmol. 1997;11:98-105.
13. Nuyts RMMA, Felten PC, Pels E, et al. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony. Am J Ophthalmol. 1994;118:225-237.
14. Gupta S, Basti S. Corneoscleral, ciliary body, and vitreoretinal toxicity after excessive instillation of mitomycin C (letter). Am J Ophthalmol. 1992;114:503-504.
15. Ewing-Chow DA, Romanchuk KG, Gilmour GR, Underhill JH, Climenhaga DB. Corneal melting after pterygium removal followed by topical mitomycin C therapy. Can J Ophthalmol. 1992;27:197-199.
16. Dunn JP, Seamone CD, Ostler HB, Nickel BL, Beallo A. Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy Am J Ophthalmol. 1991;112:343-344.
17. Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin C after pterygium surgery. Ophthalmology. 1992;99:1647-1654.
18. Siegel D, Beall H, Senekowitsch C, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 1992;31:7879-7885.
19. Ross D, Siegel D, Beall H, Mulcahy RT, Prakash AS, Gibson NW. Activation and detoxification of quinones by DT-diaphorase: bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993; 12:83-101.
20. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 1996;56:2823-2826.
21. Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res. 1998; 4:3083-3088.
22. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res. 1998;4:2065-2070.
23. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75: 69-75.
24. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852-854.
25. Siegel D, McGunness SM, Winski SL, Ross D. Genotype-phenotype relationships in a study of a polymorphism in NAD(P)H:quinone oxidoreductase. Pharmacogenetics. 1999;9:113-121.
26. Schlager JJ, Powis G. Cytosolic NAD(P)H. quinone acceptor oxidoreductase in human normal and tumor tissues: effects of cigarette smoking and alcohol. Int J Cancer. 1990;45:403-409.
27. Marin A, Lopez de Cerain A, Hamilton E, et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer. 1997;76:923-929.
28. Beyer RE, Segura-Aguilar J, Di Bernardo S, et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci USA. 1996;93:2528-2532.
29. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of a-tocopherolquinone by Human NAD(P)H:quinone oxidoreductase: the role of α-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol. 1997;52:300-305.
30. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institutes tumor cell line panel: correlation with sensitivity to mitomycin c and EO9. J Natl Cancer Inst. 1996;83:259-269.
31. Malkinson AM, Siegel D, Forrest GL, et al. Elevated DT-diaphorase activity and mRNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res. 1992;52:4752-4757.
32. Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA. Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol. 1996;50:728-735.
33. Mietz H, Addicks K, Diestelhorst M, Krieglstein GK. Extraocular application of mitomycin C in a rabbit model: cytotoxic effects on the ciliary body and epithelium. Ophthalmic Surg. 1994;25:240-244.
34. Kawashima S, Mizota A, Adachi-Usami E, Kimura T. Effects of mitomycin C on the rat retina. Doc Ophthalmol. 1996;92:229-241.
35. Del Priore LV, Kaplan HJ, Hornbeck R, Jones Z, Swinn M. Retinal pigment epithelium debridement as a model for the pathogenesis and treatment of macular degeneration. Am J Ophthalmol. 1996; 122:629-643.
36. Mietz H, Prager TC, Schweitzer C, Patrinely J, Valenzuela JR, Font RL. Effect of mitomycin C on the optic nerve in rabbits. Br J Ophthalmol. 1997;81:584-589.
37. Siegel D, Beall H, Kasai M, Arai H, Gibson NW, Ross D. pH-Dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol Pharmacol. 1993;44:1128-1134.
38. Spanswick VJ, Cummings J, Smyth JF. Enzymology of mitomycin C metabolic activation in tumor tissue Biochem Pharmacol. 1996; 51:1623-1630.
39. Sreerama L, Hedge MW, Sladek NE. Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione-S-transferases and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin Cancer Res. 1995;1:1153-1163.